SHANGHAI, Nov. 27, 2018 /PRNewswire – WuXi AppTec, a leading global pharmaceutical, biotechnology, and medical device open-access capability and technology platform, today announced that it received the 2018 Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership Award from Frost & Sullivan, a top-notch business research and consulting firm. WuXi was awarded for the second consecutive year.
The award is part of the Frost & Sullivan Best Practices Award series, which recognizes companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. WuXi has been recognized for its excellence in demonstrating innovation and strong growth performance over the years.
“Adherence to best practices in service delivery has allowed WuXi AppTec to provide timely results and enable clients to achieve drug R&D and manufacturing cost optimization,” said Sanjeev Kumar, Industry Analyst from Frost & Sullivan Transformational Health. “WuXi has succeeded in achieving consistent growth by aligning its growth strategies with changing market needs. The company’s focus on addressing customer demand, broad industry coverage, and capacity development through state-of-the-art facilities has enabled WuXi to maintain and expand its client base globally.”
“Thank you, Frost & Sullivan, for recognizing WuXi’s enabling platform we have been diligently building over the years,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “It’s an honor to serve our innovative partners around the world and help expedite the discovery and development of better medicines for patients.”
About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule drug R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, drug R&D and medical device testing, WuXi platform is enabling more than 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi’s dream that “every drug can be made and every disease can be treated.”